Skip to main content
Clinical Trials/EUCTR2012-005275-14-NO
EUCTR2012-005275-14-NO
Active, not recruiting
Phase 1

Remission in rheumatoid arthritis – assessing withdrawal of disease-modifying antirheumatic drugs in a non-inferiority design - ARCTIC REWIND

Diakonhjemmet Hospital AS0 sites360 target enrollmentFebruary 4, 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Rheumatoid arthritis (RA)
Sponsor
Diakonhjemmet Hospital AS
Enrollment
360
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 4, 2013
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Diakonhjemmet Hospital AS

Eligibility Criteria

Inclusion Criteria

  • a)Rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria (48\), Appendix 2\.
  • b)Male or non\-pregnant, non\-nursing female
  • c)\>18 years of age and \< 80 years of age
  • d)Disease duration less than five years at inclusion into ARCTIC REWIND, defined as time from first joint swelling
  • e)Sustained remission for \= 12 months according to DAS or DAS28, with documented remission status at a minimum of 2 consecutive visits during the last 18 months OR participation in the first ARCTIC trial
  • f)DAS \< 1\.6 and no swollen joints at inclusion OR participation in the first ARCTIC trial
  • g)Unchanged treatment with TNFi and/or synthetic DMARDs during the previous 12 months, with a stable or reduced dose of glucocorticosteroids OR participation in the first ARCTIC trial
  • h)Subject is capable of understanding and signing an informed consent form
  • i)Provision of written informed consent
  • Are the trial subjects under 18? no

Exclusion Criteria

  • a)Abnormal renal function, defined as serum creatinine \> 142 µmol/L in female and \> 168 µmol/L in male, or a GFR \< 40 mL/min/1\.73 m2
  • b)Abnormal liver function (defined as ASAT/ALAT \> 3 x upper normal limit), active or recent hepatitis, cirrhosis
  • c)Major co\-morbidities, such as severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3 or 4\) and/or severe respiratory diseases
  • d)Leukopenia and/or thrombocytopenia
  • e)Inadequate birth control, pregnancy, and/or breastfeeding
  • f)Indications of active TB
  • g)Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible.

Outcomes

Primary Outcomes

Not specified

Similar Trials